Resource Summary Report

Generated by NIF on Aug 3, 2026

Brilliant Violet 510(TM) anti-mouse CD4

RRID:AB_2562608
Type: Antibody

Proper Citation

BioLegend Cat# 100559, RRID:AB_2562608

Antibody Information

URL: http://antibodyregistry.org/AB_2562608

Proper Citation: BioLegend Cat# 100559, RRID:AB_2562608

Target Antigen: CD4

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 510(TM) anti-mouse CD4

Description: This monoclonal targets CD4

Target Organism: mouse

Clone ID: Clone RM4-5

Antibody ID: AB_2562608

Vendor: BioLegend

Catalog Number: 100559

Alternative Catalog Numbers: 100553

Record Creation Time: 20250819T211214+0000

Record Last Update: 20250819T221115+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 510(TM) anti-mouse CD4.

No alerts have been found for Brilliant Violet 510(TM) anti-mouse CD4.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 47 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Zhou X, et al. (2025) Potentiating anti-tumor immunity by re-engaging immune synapse molecules. Cell reports. Medicine, 6(3), 101975.

León-Letelier RA, et al. (2025) Citrullinated ENO1 Vaccine Enhances PD-1 Blockade in Mice Implanted with Murine Triple-Negative Breast Cancer Cells. Vaccines, 13(6).

Wei H, et al. (2025) AKR1D1 suppresses liver cancer progression by promoting bile acid metabolism-mediated NK cell cytotoxicity. Cell metabolism, 37(5), 1103.

Cheung JF, et al. (2025) Distinct T cell functions enable efficient immunoediting and prevent tumor emergence of developing sarcomas. Cancer cell, 43(12), 2311.

Hesterberg RS, et al. (2025) Lymphoma accelerates T cell and tissue aging. Cancer cell.

Tang K, et al. (2025) Perturbation of calreticulin potentiates CD8+ T cell-mediated antitumor immunity. The Journal of experimental medicine, 222(10).

Vasudev A, et al. (2025) Coordinated changes in stromal and hematopoietic cells that define the perinatal to juvenile transition in the mouse thymus. Cell reports, 44(12), 116677.

Simons B, et al. (2025) Clonal persistence dominates homeostatic intestinal IgA responses. Immunity, 58(12), 3061.

Cheng X, et al. (2024) Loss of ZNF408 attenuates STING-mediated immune surveillance in breast carcinogenesis. iScience, 27(7), 110276.

Ray R, et al. (2024) Eliciting a single amino acid change by vaccination generates antibody protection against group 1 and group 2 influenza A viruses. Immunity, 57(5), 1141.

Zúquete S, et al. (2024) Combined TLR2/TLR4 activation equip non-mucosal dendritic cells to prime Th1 cells with gut tropism. iScience, 27(12), 111232.

Lim YJ, et al. (2024) MicroRNA-19b exacerbates systemic sclerosis through promoting Th9 cells. Cell reports, 43(8), 114565.

Chen S, et al. (2024) Application of a bespoke monoclonal antibody panel to characterize immune cell populations in cave nectar bats. Cell reports, 43(9), 114703.

Liu M, et al. (2024) The crosstalk between macrophages and cancer cells potentiates pancreatic cancer cachexia. Cancer cell, 42(5), 885.

Jin M, et al. (2024) Dynamic allostery drives autocrine and paracrine TGF-? signaling. Cell, 187(22), 6200.

Liu Y, et al. (2024) Squalene-epoxidase-catalyzed 24(S),25-epoxycholesterol synthesis promotes trained-immunity-mediated antitumor activity. Cell reports, 43(4), 114094.

Shouse AN, et al. (2024) Interleukin-2 receptor signaling acts as a checkpoint that influences the distribution of regulatory T cell subsets. iScience, 27(12), 111248.

Arieta CM, et al. (2023) The T-cell-directed vaccine BNT162b4 encoding conserved non-spike antigens protects animals from severe SARS-CoV-2 infection. Cell, 186(11), 2392.

Tichet M, et al. (2023) Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor-reactive CD8+ T cells and reprogramming macrophages. Immunity, 56(1), 162.

Torow N, et al. (2023) M cell maturation and cDC activation determine the onset of adaptive immune priming in the neonatal Peyer's patch. Immunity, 56(6), 1220.